# Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

> **NCT05466812** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Thyroid Neoplasm Follicular
- Bone Metastases

## Interventions

- **DRUG:** Sr-89

## Key facts

- **NCT ID:** NCT05466812
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-13
- **Primary completion:** 2024-07-13
- **Final completion:** 2025-07-13
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05466812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05466812, "Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05466812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*